Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mesenchymal cell replacement corrects thymic hypoplasia in murine models of 22q11.2 deletion syndrome
Pratibha Bhalla, … , Antonio Baldini, Nicolai S.C. van Oers
Pratibha Bhalla, … , Antonio Baldini, Nicolai S.C. van Oers
Published September 22, 2022
Citation Information: J Clin Invest. 2022;132(22):e160101. https://doi.org/10.1172/JCI160101.
View: Text | PDF | Corrigendum
Research Article Genetics Immunology

Mesenchymal cell replacement corrects thymic hypoplasia in murine models of 22q11.2 deletion syndrome

  • Text
  • PDF
Abstract

22q11.2 deletion syndrome (22q11.2DS) is the most common human chromosomal microdeletion, causing developmentally linked congenital malformations, thymic hypoplasia, hypoparathyroidism, and/or cardiac defects. Thymic hypoplasia leads to T cell lymphopenia, which most often results in mild SCID. Despite decades of research, the molecular underpinnings leading to thymic hypoplasia in 22q11.2DS remain unknown. Comparison of embryonic thymuses from mouse models of 22q11.2DS (Tbx1neo2/neo2) revealed proportions of mesenchymal, epithelial, and hematopoietic cell types similar to those of control thymuses. Yet, the small thymuses were growth restricted in fetal organ cultures. Replacement of Tbx1neo2/neo2 thymic mesenchymal cells with normal ones restored tissue growth. Comparative single-cell RNA-Seq of embryonic thymuses uncovered 17 distinct cell subsets, with transcriptome differences predominant in the 5 mesenchymal subsets from the Tbx1neo2/neo2 cell line. The transcripts affected included those for extracellular matrix proteins, consistent with the increased collagen deposition we observed in the small thymuses. Attenuating collagen cross-links with minoxidil restored thymic tissue expansion for hypoplastic lobes. In colony-forming assays, the Tbx1neo2/neo2-derived mesenchymal cells had reduced expansion potential, in contrast to the normal growth of thymic epithelial cells. These findings suggest that mesenchymal cells were causal to the small embryonic thymuses in the 22q11.2DS mouse models, which was correctable by substitution with normal mesenchyme.

Authors

Pratibha Bhalla, Qiumei Du, Ashwani Kumar, Chao Xing, Angela Moses, Igor Dozmorov, Christian A. Wysocki, Ondine B. Cleaver, Timothy J. Pirolli, Mary Louise Markert, Maria Teresa de la Morena, Antonio Baldini, Nicolai S.C. van Oers

×

Figure 1

Hypoplastic embryonic thymuses isolated from 22q11.2DS mouse models have normal proportions of thymocytes and TEC subsets.

Options: View larger image (or click on image) Download as PowerPoint
Hypoplastic embryonic thymuses isolated from 22q11.2DS mouse models have...
(A–E) E18–18.5 embryonic thymuses were obtained from Tbx1+/neo2 intercrossed mouse lines. (A) Live cell images from the cardiothoracic regions of Tbx1+/+, Tbx1+/neo2, and Tbx1neo2/neo2 embryos. Thymic lobes are indicated with black arrows. An interrupted aortic arch (white arrow) often copresented with thymic hypoplasia in the Tbx1neo2/neo2 embryos (Tbx1neo2/neo2, e.g. 1). Scale bars: 50 μm. (B) Thymic tissue sections were processed for H&E staining and IHC. Top row: In the H&E-stained images, the cortical and medullary regions are dark and light purple, respectively. A medullary region is indicated by the boxed area. Scale bars: μm. Original magnification, ×10. Middle and bottom rows: With IHC, staining with antibodies selective for cortical (cytokeratin 8, red; middle row) and medullary (cytokeratin 14, green; bottom row) TECs is shown; DAPI staining revealed nuclei (blue; middle row). Coexpression of both cytokeratins (green and red) represents immature TECs. Original magnification, ×20 (middle and bottom rows). (C) T cell development was assessed by staining single-cell suspensions with antibodies selective for the CD4 and CD8 coreceptor proteins. The 4 thymocyte subsets are distinguished by electronic gating for the CD4–CD8– (DN), CD4+CD8+ (DP), and the CD4+CD8– and CD4–CD8+ (SP) subsets. (D) DN cells are further categorized by CD44 and CD25 cell-surface expression. This identifies the DN1 (CD44+CD25–), DN2 (CD44+CD25+), DN3 (CD44–CD25+), and DN4 (CD44–CD25–) subpopulations in the Tbx1+/+, Tbx1+/neo2, and Tbx1neo2/neo2 thymuses. (E) The total cell number and percentages of DP thymocytes, DN4 subpopulation of DN thymocytes, and cTECs were compared among the Tbx1+/+ (n = 7–10), Tbx1+/neo2 (n = 10–15), and Tbx1neo2/neo2 (n = 4–7) genotypes. Statistically significant differences among the 3 groups were determined by 1-way ANOVA (Brown-Forsythe and Welch tests).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts